Loss of CCDC6 Affects Cell Cycle through Impaired Intra-S-Phase Checkpoint Control

Angeliki Thanasopoulou1, Dimitrios J. Stravopodis2, Konstantinos S. Dimas3, Juerg Schwaller4, Ema Anastasiadou1*

1 Department of Genetics & Gene Therapy, Biomedical Research Foundation of Academy of Athens, Athens, Greece, 2 Department of Cell Biology & Biophysics, Faculty of Biology, University of Athens, Athens, Greece, 3 Laboratory of Pharmacology, Faculty of Medicine, University of Thessaly, Larissa, Greece, 4 Department of Biomedicine, Basel University Medical School, Basel, Switzerland

Abstract

In most cancers harboring Ccdc6 gene rearrangements, like papillary thyroid tumors or myeloproliferative disorders, the product of the normal allele is supposed to be functionally impaired or absent. To address the consequence of the loss of CCDC6 expression, we applied lentiviral shRNA in several cell lines. Loss of CCDC6 resulted in increased cell death with clear shortening of the S phase transition of the cell cycle. Upon exposure to etoposide, the cells lacking CCDC6 did not achieve S-phase accumulation. In the absence of CCDC6 and in the presence of genotoxic stress, like etoposide treatment or UV irradiation, increased accumulation of DNA damage was observed, as indicated by a significant increase of pH2A.X Ser139. 14-3-3σ, a major cell cycle regulator, was down-regulated in CCDC6 lacking cells, regardless of genotoxic stress. Interestingly, in the absence of CCDC6, the well-known genotoxic stress-induced cytoplasmic sequestration of the S-phase checkpoint CDC25C phosphatase did not occur. These observations suggest that CCDC6 plays a key role in cell cycle control, maintenance of genomic stability and cell survival and provide a rational of how disruption of CCDC6 normal function contributes to malignancy.

Introduction

Coiled-coil domain containing 6 (CCDC6, also known as H4/D10S170 or PTC1) encodes for a ubiquitously expressed protein, highly conserved across species, that is frequently rearranged in human malignancies. It was initially isolated and characterized due to its participation in RET/PTC1 oncogene, the product of the normal allele is supposed to be functionally impaired or absent. To address the consequence of the loss of CCDC6 normal function contributes to malignancy.

Results

Efficient CCDC6 silencing alters proliferation rate and significantly increases cell death

Two lentiviruses expressing different CCDC6 shRNAs were applied to HCT116, HeLa and MCF7 cells. As show in Figure 1A, expression of either shRNA, resulted in highly significant reduction of the protein levels of CCDC6. The impact of CCDC6 knock down on proliferation and survival of HCT116 cells was studied by trypan blue dye exclusion and counting the number of alive and dead cells for 4 consecutive days (Figure 1B). A slight growth reduction of CCDC6 knock down cells was observed compared to mock transduced control cells. The reduced...
growth was associated with significantly increased cell death (72 hours: \( r_{\text{sh1}} = 9.7 \times 10^{-13}, \ r_{\text{sh2}} = 3.8 \times 10^{-10} \) and 96 hours: \( r_{\text{sh1}} = 9.1 \times 10^{-10}, \ r_{\text{sh2}} = 2.4 \times 10^{-10} \)), suggesting that cells were not growth arrested but rather cycling before cell death (Figure 1B).

To further investigate the observed cell death, we performed flow cytometry gating for the cell population in subG0/G1 with less than 2n DNA content, corresponding to apoptotic and dead cells (Figure 1C). This population was significantly increased (48 hours: \( r_{\text{sh1}} = 2.8 \times 10^{-4}, \ r_{\text{sh2}} = 8.19 \times 10^{-5} \), 72 hours: \( r_{\text{sh1}} = 0.0318, \ r_{\text{sh2}} = 0.0259 \), 96 hours: \( r_{\text{sh1}} = 0.011, \ r_{\text{sh2}} = 3.9 \times 10^{-4} \)) upon CCDC6 knock down compared to the control cells, at all time points measured. We further analyzed apoptotic cell death by staining for Po-PRO and 7-AAD. The double positive population corresponding to late apoptosis was significantly increased (48 hours: \( r_{\text{sh1}} = 0.001853, \ r_{\text{sh2}} = 0.003125 \), 72 hours: \( r_{\text{sh1}} = 0.006971, \ r_{\text{sh2}} = 0.000968 \)) in CCDC6 knock down cells, furthermore suggesting that efficient silencing of CCDC6 results in apoptotic cell death. Similar results were obtained in MCF7 and HeLa cells (data not shown). Consequently, we demonstrated that absence of CCDC6 results in increased cell death without growth arrest.

**Loss of CCDC6 expression results in aberrant S-phase cell cycle progression**

To study the effect of CCDC6 knock down on cell cycle progression, we transduced HCT116 and HeLa cells with the shRNA expressing lentiviruses and analyzed cell cycle progression of the cells by PI staining, at 48, 60, 72 and 84 hours. As shown in Figure 2, alterations of all phases of the cell cycle could be observed. More specifically, we observed a consistent increase of the cell population in phases G1 and G2 and a decrease of cells in S phase of the cell cycle at all time points upon CCDC6 knock down, compared to mock-transduced cells. Similar results were observed both in HCT116 (Figure 2A & B) and in HeLa cells (Figure 2C & D).

To clarify the impact on cell cycle regulation we synchronized HCT116 cells by serum starvation for 48 hours and re-stimulated
them by adding 5% FCS to the medium. Interestingly, synchronization of the mock-transduced control cells was superior to that obtained by the CCDC6 knock down cells (Figure 2E). More specifically, the majority of the mock-transduced cells were arrested in G1 phase (84%) while a very small percentage of the cells was distributed among S (6%) and G2 phase of the cycle (4%), as expected. In contrast, upon CCDC6 knock down, the cells were mainly in G1 (78%), with a respectful 22% of cells in G2; cells in S phase were nearly undetected (1%). Moreover, 14 hours after serum stimulation the majority of the control cells are in S phase while CCDC6 knock down cells demonstrated a delay in S phase entering. 4 hours later, control and CCDC6 knock down cells showed the same profile, suggesting shorter duration of S upon CCDC6 knock down. 24 hours later, control cells were cycling normally and CCDC6 knock down cells exhibited a delay in completing G2 phase and re-entering G1.

Loss of CCDC6 expression inhibits intra-S phase checkpoint activation and results in increased cell death

The impact of CCDC6 on S-phase cell cycle progression was further addressed by treating mock-transduced and CCDC6 shRNA expressing HCT116 and HeLa cells with etoposide (20 μM), a well-established topoisomerase II inhibitor inducing DNA damage. Etoposide is known to activate intra-S phase checkpoint control depicted as a delay in S phase, followed by a G2/M arrest via activation of G2/M checkpoint [16–18]. Etoposide treatment of mock-transduced cells resulted in an initial accumulation in S phase, as early as 4 hours after etoposide addition, gradually reaching a G2 arrest 36 hours post treatment. In contrast, CCDC6 knock down cells showed a dramatic reduction of S phase accumulation, at all time points (Figure 3A). Eventually, the cells progressed and accrued in G2 phase, exhibiting increased cell death compared to the control. This was evidenced by the percentage of cells in subG0/G1, reaching 22.7% for knock down cells compared to 9.0% of mock transduced cells (Figure 3A & 3B). These results strongly suggested that the presence of CCDC6 is essential for the proper function of intra-S phase checkpoint control.

To determine the effect of CCDC6 silencing on cell survival upon etoposide-mediated genotoxic stress, the apoptotic cells were determined by Po-PRO and 7-AAD double stains. As depicted in Figure 3C, CCDC6 knock down resulted in a significant decrease of cell survival at 24 hours post etoposide treatment whereas the survival of control cells remained unaffected upon etoposide treatment.
exposure. The difference between control and CCDC6 knock down cells remained significant at 48 hours, while at 72 hours it was eliminated, as expected, due to the etoposide toxicity. As cells lacking proper S phase checkpoint regulation, accumulate DNA damage and eventually die, these observations support the necessity of CCDC6 for the proper function of the intra-S phase checkpoint control.

**CCDC6 knockdown increases susceptibility to UV-induced DNA damage**

To further investigate the contribution of CCDC6 to intra-S phase cell cycle checkpoint, we applied genotoxic stress using UV irradiation. Previous studies have shown that UV exposure leads to the activation of an intra-S phase checkpoint that senses double strand brakes (DSB) and triggers a signaling cascade of cellular repair. The expected impact on the cell cycle profile is a delay of completion of S phase leading to transient accumulation in S phase. DNA damage beyond repair capacity results in G2 arrest, cell death or senescence [19]; [20]. In this context, we treated HCT116 and HeLa cells with UV-C in a DSB inducing dosage 0,002 J/cm² and followed cell cycle progression with and without CCDC6 knock down. As expected, UV exposure of mock-transduced cells resulted in an increased population of cells in the G1 and S phase (Figure 4A). In contrast, upon shRNA-mediated CCDC6 knock down the cells did not accumulate in G1/S phase but continued cycling and entered G2 prematurely, suggesting that the UV-induced intra-S-phase checkpoint was impaired.

Moreover, CCDC6 knock down cells were more susceptible to UV-induced cell death compared to the controls, as determined by calculating the subG0/G1 population after PI staining. ≈35% of the knock down cells recorded in subG0/G1 while the control cells remained below 10% (Figure 4B), resulting in impaired cell survival (Figure 4C) reaching 60% from the initial 80%, 24 hours after treatment. In the latter time point, cell survival of control cells was unaffected. To follow DSBs induced by either UV irradiation or etoposide treatment, we also determined the expression of pH2Ax Ser139, an established marker for DSBs in the genome [21]. Loss of CCDC6 expression resulted in increased pH2Ax Ser139 levels upon irradiation with abundant expression as early as 2 hours post UV treatment. At the same time point, pH2Ax Ser139 levels remained undetectable in mock-transduced control cells. Overall, in all time points analyzed, the pH2Ax Ser139 protein levels were higher in the absence of CCDC6 expression (Figure 4D). Likewise, upon etoposide treatment, the pH2Ax Ser139 protein levels were elevated in the absence of CCDC6 (Figure 4D). Additionally, we visualized pH2Ax Ser139 expression by confocal microscopy and demonstrated that the levels of pH2Ax Ser139 were elevated upon knock down of CCDC6 expression in accordance to the Western blot results. Moreover, the nuclear configuration of this protein changed in the absence of CCDC6, pH2Ax Ser139 forming distinct foci. These observations furthermore suggest that CCDC6 knock down increases susceptibility to DNA damage upon genotoxic stress.
CCDC6 knock down affects the 14-3-3 and CDC25C regulators of G2/M transition

The above results demonstrate that CCDC6 contributes to the activation of the S phase checkpoints. Due to its absence there is acceleration to S phase and premature entrance to G2/M. The transition to G2/M during normal cell cycle is regulated by the activation of CDC25C. Previous studies have shown that, inactive Ser216-phosphorylated CDC25C is sequestered to the cytoplasm by the 14-3-3 proteins. Once mitosis is activated, cytoplasmic sequestration of CDC25C is inhibited by a CDC2-mediated phosphorylation of CDC25C at Ser214, leading to disassociation of 14-3-3s and CDC25C [22–25].

We followed these S-phase checkpoint mediators, CDC25C and 14-3-3σ, upon exposure of HCT116 cells to etoposide (20 μM) or irradiated with UV (0.002 J/cm²) for 2, 6 or 24 hours and the untreated controls were resolved on a SDS-PAGE and probed for pH2Ax Ser139. Upon UV irradiation, pH2Ax Ser139 levels arise earlier and to a higher extent in CCDC6 knockdown cells compared to the control. UV irradiation is causing high levels of pH2Ax Ser139 even in 2 hours after irradiation in CCDC6 knockdown cells. The effect is similar upon etoposide treatment, although less dramatic. Increased basal levels and nuclear foci of pH2Ax Ser139 are present in CCDC6 knockdown cells, even in the absence of any additional treatment.

Moreover, in CCDC6 knockdown the protein levels of 14-3-3σ decreased and then increased upon etoposide treatment. In contrast, in mock-transduced cells the 14-3-3σ levels remained unchanged for 24 hours. More interestingly, absence of CCDC6 altered the localization of these molecules (Figures 5B & G). More specifically, we followed the subcellular localization of CDC25C upon etoposide treatment at different time points (0, 4, 8, 12, 24, 48 hours). Cytosolic sequestration of CDC25C in cells lacking CCDC6 was not obvious in any of the time points checked whereas mock-transduced cells exhibited mainly cytosolic localization of CDC25C at Ser214, leading to disassociation of 14-3-3σ and CDC25C [22–25].

We followed these S-phase checkpoint mediators, CDC25C and 14-3-3σ, upon exposure of HCT116 cells to etoposide (20 μM), in the presence or absence of CCDC6 using Western blotting and confocal microscopy. As shown in Figure 5A, CDC25C is steadily increased in a course of time, upon etoposide treatment. However, CCDC6 knockdown resulted in an earlier increase of the CDC25C protein levels compared to mock-transduced cells.
Discussion

Several lines of evidence suggested that CCDC6-related malignancies are developed upon loss of CCDC6 normal function. First, the majority (>90%) of tumors bearing CCDC6 fusion genes do not express CCDC6 from the normal allele [10]. In addition, in the presence of the chimeric molecule, endogenous expressed normal CCDC6 protein seems to heterodimerize with the fusion product, suggesting a dominant negative effect of the fusion on CCDC6 normal function [13,26].

Moreover, several public databases reported that a significant number of head and neck cancers exhibit considerable down-regulation of CCDC6 (www.oncomine.org, www.proteinatlas.org). Under this perspective, we have silenced expression of CCDC6 in several cell lines using a highly efficient shRNA knockdown strategy. Loss of CCDC6 resulted in apoptotic cell death with only a minor reduction in proliferation. We also reported that CCDC6 is important for normal cell cycle progression and proper function of checkpoint controls. In the absence of CCDC6, intra S phase control was deficient and this

Figure S. CCDC6 knock down results in altered cellular localization of CDC25C and accelerated G2/S transition upon etoposide-mediated genotoxic stress. Control and CCDC6 knock down HCT116 cells were treated with etoposide (20 μM). (A) Cell lysates of HCT116 cells treated with etoposide (20 μM) for 2, 4, 8, 12 and 24 hours and mock control treated with DMSO vehicle were resolved on a SDS-PAGE and probed for 14-3-3σ and CDC25C. 14-3-3σ protein levels were down-regulated in the absence of CCDC6 protein expression and the CDC25C protein level regulation was altered. (B) Cells grown on cover slips were exposed to etoposide for 4, 8, 12, 24 hours, fixed and stained for CDC25C. In mock cells, CDC25C is kept in the cytosol upon etoposide treatment at 8 and 12 hours but is localized in the nucleus in the absence of CCDC6. (C) Cells exposed to etoposide for 12 hours were co-stained for CDC25C and 14-3-3σ. CDC25C is kept in the cytosol upon etoposide treatment and exhibits co-localization with 14-3-3σ (seen in yellow) but enters the nucleus in the absence of CCDC6.

doi:10.1371/journal.pone.0031007.g005
effect was enhanced upon DNA damage induced by etoposide or UV-irradiation.

A key regulator of the S phase duration and the transition to G2 is 14-3-3σ and its complexes to several partner proteins. 14-3-3 ligand association triggers a phosphorylation cascade resulting in cytoplasmic sequestration of the CDC25-B, CDC25-C phosphatases. Due to their location, the latter are kept inactive and unable to reach their targets, Cdk1/cyclin B1 and MPF complexes [27; [28]. Upon loss of CCDC6, we observed downregulation of 14-3-3σ and altered regulation and localization of CDC25C. In fact, CDC25C enters the nucleus, were it triggers mitosis by activation of the Cdk1/cyclin B complex. These observations suggest that CCDC6 is implicated in the regulation of normal both cell cycle progression and DNA repair mechanisms most probably through co-operation with 14-3-3σ. Interestingly, a recent proteomics study proposed direct physical interaction of CCDC6 with 14-3-3σ in a PI3K kinase specific manner [29].

Cell cycle checkpoints are implemented to safeguard the genome from accumulation of genetic errors. S (synthesis) phase is undoubtedly the most vulnerable period of the cell cycle division [30] and its checkpoints are the most significant for preventing genetic instability [31]. Extensive literature shows that malfunctioned S phase and thus aberrant DNA replication can lead to increased mutagenesis and also cell death in mitosis [32]. The fact that CCDC6 is highly implicated in chromosomal rearrangements could be an additional link to its role in genomic stability and supports our findings concerning S phase deficiency upon loss of CCDC6 [33]. The spatial contiguity between CCDC6 and RET and also their location at DNA fragile sites have been used for the high frequency of RET/PTC1 rearrangements [34–36]. Our data suggest, that loss of CCDC6 function can create a prosperous environment for the formation of cancer [15,26,37,38]. Cells depleted for CCDC6 show increased cell death in presence or absence of genotoxic stress. These cells do not arrest in G1 or S phase upon DNA damage as expected. They proceed with DNA synthesis resulting in accumulation of DNA damage, as demonstrated by an increase of p53α S139 protein levels. Our results are in agreement with previous work showing that CCDC6 downregulation and treatment with γ-radiation resulted in increased BrdU incorporation and staining for the p3H mitosis marker [15]. However, increased genotoxic stress-mediated DNA damage and cell death upon CCDC6 knock down cells has not been observed in the latter study. This discrepancy might be due to the higher knock down efficiency in the here presented experiments where the protective effects of CCDC6 were abolished.

Interestingly, similar cell cycle effects phenocopying CCDC6 knock down have been previously reported in leukemic cells expressing the BCR/ABL tyrosine kinase fusion oncprotein [39,40]. In fact expression of BCR/ABL seems also to increase DNA double-strand damage after etoposide treatment and lead to a defect in an intra-S phase checkpoint. Therefore, it will be interesting to study whether expression of the PTC1 oncogenic tyrosine kinase results in similar cell cycle checkpoint defects. Therefore, additional studies should be performed to address whether loss of normal CCDC6 might be a more common principle for other constitutively active oncogenic kinase fusions beyond the CCDC6 fusions to RET or PDGFR.

Taken together, our work suggests that loss of CCDC6 results in S phase deregulation that impairs the ability of the cell to maintain genomic integrity and creates a prosperous ground for genomic instability [30,41–43]. Further specification of the exact pathways in which CCDC6 is implicated and identification of its interacting partners will be necessary to unravel the molecular mechanisms of cancers, harboring CCDC6 alterations.

Materials and Methods

Cell culture and treatments

Different cell lines, such as HCT116, HeLa, MCF7 and 293T were cultured as a monolayer in Dulbecco’s Minimal Essential Medium (DMEM) supplemented with 10% Fetal Calf Serum, 1%P/S and 1% L-Glutamine (Invitrogen, Paisley, UK). The cells were incubated at 37°C and 5% CO₂.

Synchronisation of HCT116s was achieved through serum deprivation for 48 hours. The cells were plated on a 6 well plate (3 x 10⁶ cells/well) and stimulated with DMEM supplemented with 5% of FCS. They were harvested at the indicated time points and the cell cycle was analysed.

Cells in culture were UV irradiated at 0.002 J/cm² using a 254 nm lamp of a UV Stratalinker 2400 (Stratagene/Agilent Technologies, Santa Clara, CA, USA).

Cells were treated with 20 μM etoposide (Sigma/Aldrich, St. Louis, MO, USA) for the selected time points and cell cycle and apoptotic assays were performed.

Lentiviral shRNA constructs, viral production and cell transduction

Silencing of Ccdc6 was accomplished using commercially available shRNA lentiviral based constructs (TRCN 0000038331 and TRCN0000038328) from Sigma (Sigma/Aldrich, St. Louis, MO, USA). The empty lentiviral vector TRC1 (Sigma/Aldrich, St. Louis, MO, USA) was applied as a control.

For the lentiviral supernatant production, HEK-299T cells maintained in DMEM supplemented with 5% FCS without antibiotics, on 10 cm culture plates to ~60% confluency. Sixteen hours later transfection of HEK-293T cells took place. As a transfection reagent Lipofectamine (Invitrogen, Carlsbad, CA, USA) was used according to the manufacturer’s protocol. 3 μg of the envelop plasmid pMD2G, 3 μg of the packaging plasmid pMDIpsRRE, 2.5 μg of the Rev-expression plasmid pRS7/Rev (Addgene, Cambridge, MA, USA) and 10 μg of the shRNA lentiviral construct were added in 1 mL of DMEM medium, serum and antibiotics free. 40 μL of lipofectamine was diluted in 1 mL of DMEM without serum and antibiotics and incubated for 5 min. DNA and lipofectamine parts were mixed and incubated for 20 min before added to the HEK299T cells. 24 hours later, the medium was discarded and replaced with 5 mL of DMEM with 10% FCS, without antibiotics. 24 hours later the medium was collected into a 15 mL tube and 5 mL of medium were added to the plate and the same step was repeated at 48 hours. The lentivirus-containing supernatant was filtered through a 20 μM pore filter, aliquoted to 1 mL cryotubes and quickly frozen down in liquid nitrogen. Virus was stored at −80°C.

HCT116s, HeLas and MCF7s were plated in 6 well plates (5 x 10⁴ cells/well) and 16 hours later were viral transduced. This was performed using 1 mL of lentiviral supernatant, diluted in 1 mL of DMEM complete medium and 4 μL of protein sulphate. Cells were centrifuged at 2,500 rpm (Heraeus Biofuge stratos centrifuge) for 90 min at RT. The medium was replaced with fresh complete DMEM and changed again 24 hours later.

Fixation and immunostaining

Cells were cultured on cover slips, coated with polylysine. Fixation was performed in 4% paraformaldehyde (Sigma/Aldrich, St. Louis, MO, USA) solution in PBS, incubated for 10 min at RT. The excess paraformaldehyde was discarded after washing the cells three times with PBS. Permeabilisation was achieved through incubation in 0.1% Triton-X 100 solution for 10 min and then in 0.5% Triton-X 100 (Sigma/Aldrich, St. Louis, MO, USA)
for 30 min. The fixed cells were incubated in 5% BSA blocking solution for 1 hour. Incubation was performed for 16 hours at 4°C in a solution containing 0.3% Triton-X100, 0.5% BSA and the indicated primary antibody in the appropriate dilution. After washing three times with 0.3% Triton-X in PBS, cells were incubated with the secondary antibody diluted in 0.5% Triton-X in PBS and 0.5% BSA for 2 hours. The cells were washed on the cover slips and put on a slide by adding on top a droplet of clearmounting medium (Invitrogen, Carlsbad, CA, USA). The secondary antibodies used were anti-goat FITC from ZYMED, anti-mouse Alexa 555, anti-rabbit Alexa 488 from Invitrogen (Invitrogen, Carlsbad, CA, USA).

Flow cytometric analysis

Cell death and apoptosis was measured by Membrane Permeability/Dead Cell Apoptosis Kit with Po-PRO-1 and 7-AAD Apoptosis for Flow Cytometry (Invitrogen, Carlsbad, CA, USA) as recommended by the manufacturer, using a DAKO CYAN flow cytometer (DAKO, Fort Collins, CO, USA). Cell cycle profiling was carried out by Propidium Iodide staining and analysed by FlowJo Software. The quantification of apoptosis was performed via analysis of the subG0. Cells were fixed with 70% ice cold ethanol and kept at -20°C over night. Then, cells were washed twice with PBS and resuspended in PI solution containing 1 mg/mL propidium iodide, 100 μg/mL RNase A. 0.001% Triton-X 100 in PBS at a concentration of 10⁶ cells/mL, incubated for 45 min at 37°C in the dark and analysed using a Dako CYAN FACS machine. The propidium iodide fluorescence emission signal was detected in the FL3 channel. At least 20,000 events were acquired.

Confocal microscopy

Confocal fluorescence images were obtained by a Zeiss LSM710 (Zeiss, Thornwood, NY microscope) with a 63x objective. Images were analysed by Zeiss software.

Antibodies and Western Blot analysis

Cells were harvested and lysed in RIPA (200 mM NaCl, 10 mM Tris-Hcl at pH 7.5, 0.1% SDS, 1% Triton X-100) and complete protease and phosphatase inhibitor cocktail tablets (Hoffmann-La Roche NJ, USA). The protein concentration was determined by a Bradford assay (BIORAD). Equal amounts of proteins were electrophorated and separated by 12% SDS-PAGE gels, followed by transfer onto nitrocellulose membranes. Immunoblotting was performed using various antibodies. Blotted proteins were visualized with the aid of an enhanced chemiluminescence kit (Amersham, Piscataway, NJ, USA) and imaged with Kodak Biomax Light Films (Sigma/Aldrich, St. Louis, MO, USA).

Flow cytometric analysis

Cell death and apoptosis was measured by Membrane Permeability/Dead Cell Apoptosis Kit with Po-PRO-1 and 7-AAD Apoptosis for Flow Cytometry (Invitrogen, Carlsbad, CA, USA) as recommended by the manufacturer, using a DAKO CYAN flow cytometer (DAKO, Fort Collins, CO, USA). Cell cycle profiling was carried out by Propidium Iodide staining and analysed by FlowJo Software. The quantification of apoptosis was performed via analysis of the subG0. Cells were fixed with 70% ice cold ethanol and kept at -20°C over night. Then, cells were washed twice with PBS and resuspended in PI solution containing 1 mg/mL propidium iodide, 100 μg/mL RNase A. 0.001% Triton-X 100 in PBS at a concentration of 10⁶ cells/mL, incubated for 45 min at 37°C in the dark and analysed using a Dako CYAN FACS machine. The propidium iodide fluorescence emission signal was detected in the FL3 channel. At least 20,000 events were acquired.

Confocal microscopy

Confocal fluorescence images were obtained by a Zeiss LSM710 (Zeiss, Thornwood, NY microscope) with a 63x objective. Images were analysed by Zeiss software.

References

1. Kondo T, Ezato S, Asa S (2006) Pathogenetic mechanisms in thyroid follicular-cell neoplasia. J Natl Cancer Inst 8: 292–306.
2. Kulkarni S, Heath C, Parker S, Chase A, Iqbal S, et al. (2000) Fusion of H4/D10S170 to the platelet-derived growth factor receptor beta in BCR-ABL-negative myeloproliferative disorders with a t(5;10)(q35;p21). Cancer Res 60: 3392–3398.
3. Schwaller J, Anastasiadou E, Caim D, Kutok J, Wojiski S, et al. (2001) H4(D10S170), a gene frequently rearranged in papillary thyroid carcinoma, is fused to the platelet-derived growth factor receptor beta gene in atypical chronic myeloid leukemia with t(5;10)(q35;q22). Blood 97: 3910–3918.
4. Drechsler M, Hildebrandt B, Kandeng A, Gemming U, Roer-Pokora B (2007) Fusion of H4/D10S170 to PDGFReceptor in a patient with chronic myelomonocytic leukemia and long-term responsiveness to imatinib. Ann Hematol 86: 353–354.
5. Santoro M, Chiappetta G, Cerrato A, Salvatore D, Zhang L, et al. (1996) Development of thyroid papillary carcinomas secondary to tissue-specific expression of the RET/PTC1 oncogene in transgenic mice. Oncogene 12: 1821–1826.
6. Salvatore D, Barone MV, Salvatore G, Melillo RM, Chiappetta G, et al. (2000) Tyrosines 1015 and 1062 are in vivo autophosphorylation sites in ret and ret–oncogene products. J Biol Chem 275: 18211–18218.
7. Mizuno T, Iwamoto KS, Kyoizumi S, Nagamura H, Shinohara T, et al. (2000) Preferential induction of RET/PTC1 rearrangement by X-ray irradiation. Oncogene 19: 438–443.
8. Muzumdo T, Iwamoto KS, Sagamato S, Nagamura H, Shinohara T, et al. (2000) Preferential induction of RET/PTC1 rearrangement by X-ray irradiation. Oncogene 19: 438–443.
9. Nikiforov YE (2002) RET/PTC rearrangement in thyroid tumors. Endocr Pathol 13: 3–16.
10. Viglietto G, Chiappetta G, Martinez-Tello I, Falkoagsh FH, Tallini G, et al. (1995) RET/PTC oncogene activation is an early event in thyroid carcinogenesis. Oncogene 11: 1207–1210.
11. Shello OM, O’Leary JJ, Sweeney EC (2000) Assessment of ret/PTC-1 rearrangements in neoplastic thyroid tissue using TaqMan RT-PCR. J Pathol 192: 52–56.
12. Elisei R, Romei C, Vorontsova T, Cosci B, Veremeychik V, et al. (2001) RET/PTC rearrangements in thyroid nodules: studies in irradiated and not irradiated, malignant and benign thyroid lesions in children and adults. J Clin Endocrinol Metab 86: 3211–3216.
13. Guerra A, Sapio MR, Marotta V, Campanile E, Moretti MI, et al. (2011) Prevalence of RET/PTC rearrangement in benign and malignant thyroid nodules and its clinical application. Endocr J 58: 31–38.
14. Dong G, Li Y, Smanak PA, Fithian L, Xiong S, et al. (1995) Characterization of the promoter region and oligomerization domain of H4(D10S170), a gene frequently rearranged with the ret proto-oncogene. Oncogene 10: 1781–1787.
15. Celeri A, Cerrato A, Merola F, Vitaglione D, Vecchio G, et al. (2004) H4(D10S170), a gene frequently rearranged with RET in papillary thyroid carcinomas: functional characterization. Oncogene 25: 109–121.
16. Merola F, Pennillalli F, Pacelli R, Vecchio G, Fusco A, et al. (2007) Involvement of H4(D10S170) protein in ATM-dependent response to DNA damage. Oncogene 26: 6167–6175.
17. Niitsu JI (2009) Targeting DNA topoisomerase II in cancer chemotherapy. Nat Rev Cancer 9: 338–350.
18. Kaufmann WK (1998) Human topoisomerase II function, tyrosine phosphorylation and cell cycle regulation. Proc Soc Exp Biol Med 217: 327–334.
19. Bartek J, Lukas J (2001) Mammalian G1- and S-phase checkpoints in response to DNA damage. Curr Opin Cell Biol 13: 738–747.
20. Rodier F, Coppe JP, Patil CK, Hoeijmakers WA, Munoz DP, et al. (2009) DNA double-strand breaks: from untangling to clinical applications. Curr Opin Cell Biol 21: 327–334.
21. Sharpless NE, DePinho RA (2005) Cancer: crime and punishment. Nature 436: 636–637.
22. Rodier F, Coppe JP, Patil CK, Hoijnakers WA, Munoz DP, et al. (2009) Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion. Nat Cell Biol 11: 973–979.
23. Mah IJ, El-Osta A, Karagiamnis TC (2010) gammaH2AX: a sensitive molecular marker of DNA damage and repair. Leukemia 24: 679–686.
24. Chan TA, Hermekeing H, Langauer C, Knizler KW, Vogelstein B (1999) 14-3-3Sigma is required to prevent mitotic catastrophe after DNA damage. Nature 401: 616–620.
25. Hermekeing H, Benzinger A (2006) 14-3-3 proteins in cell cycle regulation. Semin Cancer Biol 16: 183–192.
26. Hermekeing H (2003) The 14-3-3 cancer connection. Nat Rev Cancer 3: 931–943.
25. Oudros R, Lobjois V, Ducommun B (2007) CDC25 phosphatases in cancer cells: key players? Good targets? Nat Rev Cancer 7: 495–507.
26. Greco M, Cerrato A, Santoro M, Fusco A, Melillo RM, et al. (1994) Cloning and characterization of HH-D108170, a gene involved in RET rearrangements in vivo. Oncogene 9: 2351–2353.
27. Bulavin DV, Higashimoto Y, Demidenko ZN, Meek S, Graves P, et al. (2003) Dual phosphorylation controls Cdc25 phosphatases and mitotic entry. Nat Cell Biol 5: 545–551.
28. Takizawa CG, Morgan DO (2000) Control of mitosis by changes in the subcellular location of cyclin-B1-Cdk1 and Cdc25C. Curr Opin Cell Biol 12: 630–635.
29. Dubois F, Vandermeere F, Gernez A, Murphy J, Toth R, et al. (2009) Differential 14-3-3 affinity capture reveals new downstream targets of phosphatidylinositol 3-kinase signaling. Mol Cell Proteomics 8: 2487–2499.
30. Bartek J, Lukas C, Lukas J (2004) Checking on DNA damage in S phase. Nat Rev Mol Cell Biol 5: 792–804.
31. Myung K, Chen G, Kolodner RD (2001) Multiple pathways cooperate in the suppression of genome instability in Saccharomyces cerevisiae. Nature 411: 1073–1076.
32. Lau E, Jiang W (2006) Is there a pre-RC checkpoint that cancer cells lack? Cell Cycle 5: 1662–1666.
33. Penserga ET, Skorski T (2007) Fusion tyrosine kinases: a result and cause of genomic instability. Oncogene 26: 11–20.
34. Nikiforova MN, Stringer JR, Blough R, Medvedovic M, Fagin JA, et al. (2000) Proximity of chromosomal loci that participate in radiation-induced rearrangements in human cells. Science 290: 138–141.
35. Savage JR (2000) Cancer. Proximity matters. Science 290: 62–63.
36. Gandhi M, Dillon LW, Pramanik S, Nikiforov YE, Wang YH (2010) DNA breaks at fragile sites generate oncogenic RET/PTC rearrangements in human thyroid cells. Oncogene 29: 2272–2280.
37. Leone V, Manuso G, Pierantoni GM, Tornincasa M, Merolla F, et al. (2010) CDC6 represses CREB1 activity by recruiting histone deacetylase 1 and protein phosphatase 1. Oncogene 29: 4341–4351.
38. Puxeddu E, Zhao G, Stringer JR, Medvedovic M, Moretti S, et al. (2005) Characterization of novel non-clonal intrachromosomal rearrangements between the H4 and PTEN genes (H4/PTEN) in human thyroid cell lines and papillary thyroid cancer specimens. Mutat Res 570: 17–32.
39. Dierov J, Dierova R, Carroll M (2004) BCR/ABL translocates to the nucleus and disrupts an ATR-dependent intra-S phase checkpoint. Cancer Cell 5: 275–285.
40. Dierov J, Sanchez PV, Burke BA, Padilla-Nash H, Putt ME, et al. (2009) BCR/ABL induces chromosomal instability after genotoxic stress and alters the cell death threshold. Leukemia 23: 279–286.
41. Shen Z (2011) Genomic instability and cancer: an introduction. J Mol Cell Biol 3: 1–3.
42. Shimada M, Nakanishi M (2006) DNA damage checkpoints and cancer. J Mol Histol 37: 253–260.
43. Motoyama N, Naka K (2004) DNA damage tumor suppressor genes and genomic instability. Curr Opin Genet Dev 14: 11–16.